EMBO Molecular Medicine (Dec 2020)
Immunodynamics of explanted human tumors for immuno‐oncology
- Agathe Dubuisson,
- Jean‐Eudes Fahrner,
- Anne‐Gaëlle Goubet,
- Safae Terrisse,
- Nicolas Voisin,
- Charles Bayard,
- Sebastien Lofek,
- Damien Drubay,
- Delphine Bredel,
- Séverine Mouraud,
- Sandrine Susini,
- Alexandria Cogdill,
- Lucas Rebuffet,
- Elise Ballot,
- Nicolas Jacquelot,
- Vincent Thomas de Montpreville,
- Odile Casiraghi,
- Camélia Radulescu,
- Sophie Ferlicot,
- David J Figueroa,
- Sapna Yadavilli,
- Jeremy D Waight,
- Marc Ballas,
- Axel Hoos,
- Thomas Condamine,
- Bastien Parier,
- Christophe Gaudillat,
- Bertrand Routy,
- François Ghiringhelli,
- Lisa Derosa,
- Ingrid Breuskin,
- Mathieu Rouanne,
- Fabrice André,
- Cédric Lebacle,
- Hervé Baumert,
- Marie Wislez,
- Elie Fadel,
- Isabelle Cremer,
- Laurence Albiges,
- Birgit Geoerger,
- Jean‐Yves Scoazec,
- Yohann Loriot,
- Guido Kroemer,
- Aurélien Marabelle,
- Mélodie Bonvalet,
- Laurence Zitvogel
Affiliations
- Agathe Dubuisson
- Institut Gustave Roussy
- Jean‐Eudes Fahrner
- Institut Gustave Roussy
- Anne‐Gaëlle Goubet
- Institut Gustave Roussy
- Safae Terrisse
- Institut Gustave Roussy
- Nicolas Voisin
- Institut Gustave Roussy
- Charles Bayard
- Institut Gustave Roussy
- Sebastien Lofek
- Institut Gustave Roussy
- Damien Drubay
- Institut Gustave Roussy
- Delphine Bredel
- Institut Gustave Roussy
- Séverine Mouraud
- Institut Gustave Roussy
- Sandrine Susini
- Institut Gustave Roussy
- Alexandria Cogdill
- Institut Gustave Roussy
- Lucas Rebuffet
- Institut Gustave Roussy
- Elise Ballot
- Cancer Biology Transfer Platform, Centre Georges‐François Leclerc
- Nicolas Jacquelot
- Institut Gustave Roussy
- Vincent Thomas de Montpreville
- Service d'Anatomie et cytologie pathologiques, Hôpital Marie Lannelongue
- Odile Casiraghi
- Departement de Biologie et Pathologie Médicales, Gustave Roussy Cancer Campus
- Camélia Radulescu
- Service d'Anatomie et cytologie pathologiques, Hôpital Foch
- Sophie Ferlicot
- Service d'Anatomie et cytologie pathologiques, Hôpital Bicêtre
- David J Figueroa
- Oncology R&D, GlaxoSmithKline, Collegeville
- Sapna Yadavilli
- Oncology R&D, GlaxoSmithKline, Collegeville
- Jeremy D Waight
- Oncology R&D, GlaxoSmithKline, Collegeville
- Marc Ballas
- Oncology R&D, GlaxoSmithKline, Collegeville
- Axel Hoos
- Oncology R&D, GlaxoSmithKline, Collegeville
- Thomas Condamine
- Incyte Research Institute
- Bastien Parier
- Service de Chirurgie urologique, Hôpital Bicêtre
- Christophe Gaudillat
- Service d'Urologie, Hôpital Saint Joseph
- Bertrand Routy
- Division of Oncology, Department of Medicine, Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM)
- François Ghiringhelli
- Cancer Biology Transfer Platform, Centre Georges‐François Leclerc
- Lisa Derosa
- Institut Gustave Roussy
- Ingrid Breuskin
- Département de Chirurgie, Gustave Roussy, Université Paris‐Saclay
- Mathieu Rouanne
- Institut Gustave Roussy
- Fabrice André
- Institut Gustave Roussy
- Cédric Lebacle
- Service de Chirurgie urologique, Hôpital Bicêtre
- Hervé Baumert
- Institut Gustave Roussy
- Marie Wislez
- AP‐HP, Centre – Université de Paris, Hôpital Cochin, Unité d'Oncologie Thoracique, Service de Pneumologie
- Elie Fadel
- Service de Chirurgie Thoracique, Hôpital Marie Lannelongue
- Isabelle Cremer
- Team Inflammation, Complement and Cancer, INSERM, Centre de Recherche des Cordeliers
- Laurence Albiges
- Institut Gustave Roussy
- Birgit Geoerger
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris‐Saclay
- Jean‐Yves Scoazec
- Institut Gustave Roussy
- Yohann Loriot
- Institut Gustave Roussy
- Guido Kroemer
- Institut Gustave Roussy
- Aurélien Marabelle
- Institut Gustave Roussy
- Mélodie Bonvalet
- Institut Gustave Roussy
- Laurence Zitvogel
- Institut Gustave Roussy
- DOI
- https://doi.org/10.15252/emmm.202012850
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
Abstract Decision making in immuno‐oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predicting the best combinatorial regimen remains an unmet medical need. Here, we report a multiplex functional and dynamic immuno‐assay based on the capacity of the TME to respond to ex vivo stimulation with twelve immunomodulators including immune checkpoint inhibitors (ICI) in 43 human primary tumors. This "in sitro" (in situ/in vitro) assay has the potential to predict unresponsiveness to anti‐PD‐1 mAbs, and to detect the most appropriate and personalized combinatorial regimen. Prospective clinical trials are awaited to validate this in sitro assay.
Keywords
